GeoVax Labs, Inc., a biotechnology firm specializing in vaccine development, announced the issuance of U.S. Patent No. 12,329,808 for its innovative vaccine construct designed to prevent malaria. This patent underscores the company's commitment to addressing global health challenges through its multi-antigenic vaccine platform. The patented technology involves a recombinant Modified Vaccinia Ankara (MVA) viral vector that expresses immunogenic proteins from Plasmodium falciparum, the parasite responsible for malaria. This approach facilitates the in vivo assembly of virus-like particles (VLPs), enhancing the vaccine's potency by inducing both humoral and T-cell responses.
David Dodd, President and CEO of GeoVax, highlighted the significance of this patent in advancing vaccines for high-consequence pathogens, emphasizing its role in pandemic preparedness and global health security. With over 135 granted or pending patent applications across various fields, GeoVax strengthens its position in the biotechnology sector, particularly in oncology, infectious diseases, and biodefense. The company's portfolio includes protections for its Gedeptin® oncolytic cancer therapy and MVA-based vaccines targeting diseases such as COVID-19, Mpox/smallpox, and Ebola.
Malaria continues to pose a severe threat to global health, especially in sub-Saharan Africa, where it causes over 600,000 deaths annually. GeoVax's MVA-based platform offers a promising solution by potentially providing durable immunity against malaria and other emerging pathogens. This development not only represents a leap forward in vaccine technology but also aligns with global efforts to combat infectious diseases that disproportionately affect vulnerable populations.
